Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Estimation of forest aboveground biomass and uncertainties by integration of field measurements, airborne LiDAR, and SAR and optical satellite data in Mexico.

Urbazaev M, Thiel C, Cremer F, Dubayah R, Migliavacca M, Reichstein M, Schmullius C.

Carbon Balance Manag. 2018 Feb 21;13(1):5. doi: 10.1186/s13021-018-0093-5.

2.

Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.

Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schlüter G, Gencik M, Überlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M.

Br J Cancer. 2015 Apr 14;112(8):1392-7. doi: 10.1038/bjc.2015.75. Epub 2015 Mar 5.

3.

Natural diversity in daily rhythms of gene expression contributes to phenotypic variation.

de Montaigu A, Giakountis A, Rubin M, Tóth R, Cremer F, Sokolova V, Porri A, Reymond M, Weinig C, Coupland G.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):905-10. doi: 10.1073/pnas.1422242112. Epub 2014 Dec 29.

4.

Evening expression of arabidopsis GIGANTEA is controlled by combinatorial interactions among evolutionarily conserved regulatory motifs.

Berns MC, Nordström K, Cremer F, Tóth R, Hartke M, Simon S, Klasen JR, Bürstel I, Coupland G.

Plant Cell. 2014 Oct;26(10):3999-4018. doi: 10.1105/tpc.114.129437. Epub 2014 Oct 31.

5.

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.

Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren AO, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor MD, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister SM.

Acta Neuropathol. 2014 Jul;128(1):137-49. doi: 10.1007/s00401-014-1276-0. Epub 2014 May 4.

6.

Low-dose S-ketamine added to propofol anesthesia for magnetic resonance imaging in children is safe and ensures faster recovery--a prospective evaluation.

Eich C, Verhagen-Henning S, Roessler M, Cremer F, Cremer S, Strack M, Russo SG.

Paediatr Anaesth. 2011 Feb;21(2):176-8. doi: 10.1111/j.1460-9592.2010.03489.x. No abstract available.

PMID:
21210891
7.

New cytogenetically visible copy number variant in region 8q21.2.

Manvelyan M, Cremer FW, Lancé J, Kläs R, Kelbova C, Ramel C, Reichenbach H, Schmidt C, Ewers E, Kreskowski K, Ziegler M, Kosyakova N, Liehr T.

Mol Cytogenet. 2011 Jan 5;4(1):1. doi: 10.1186/1755-8166-4-1.

8.

A 439 kb-sized homozygous deletion in 17p13.3 leading to biallelic loss of the ASPA as cause of Canavan disease detected by SNP-array analysis.

Caliebe A, Vater I, Plendl H, Gesk S, Siebert R, Cremer FW, Klein-Hitpass L.

Mol Genet Metab. 2010 Feb;99(2):184-5. doi: 10.1016/j.ymgme.2009.10.011. Epub 2009 Oct 20. No abstract available.

PMID:
19932039
9.

Distinct patterns of genetic variation alter flowering responses of Arabidopsis accessions to different daylengths.

Giakountis A, Cremer F, Sim S, Reymond M, Schmitt J, Coupland G.

Plant Physiol. 2010 Jan;152(1):177-91. doi: 10.1104/pp.109.140772. Epub 2009 Nov 4.

10.

Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members.

Keller M, Jost R, Haunstetter CM, Sattel H, Schroeter C, Bertsch U, Cremer F, Kienle P, Tariverdian M, Kloor M, Gebert J, Brechtel A.

Clin Genet. 2008 Nov;74(5):414-24. doi: 10.1111/j.1399-0004.2008.01089.x.

PMID:
18954412
11.

Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Belle S, Han F, Condomines M, Christensen O, Witzens-Harig M, Kasper B, Kleist C, Terness P, Moos M, Cremer F, Hose D, Ho AD, Goldschmidt H, Klein B, Hundemer M.

Eur J Haematol. 2008 Jul;81(1):26-35. doi: 10.1111/j.1600-0609.2008.01076.x. Epub 2008 Mar 19.

12.

Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma.

Hillengass J, Zechmann CM, Nadler A, Hose D, Cremer FW, Jauch A, Heiss C, Benner A, Ho AD, Bartram CR, Kauczor HU, Delorme S, Goldschmidt H, Moehler TM.

Int J Cancer. 2008 Jun 15;122(12):2871-5. doi: 10.1002/ijc.23455.

13.

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, Moos M, Bila J, Bartram CR, Ho AD, Goldschmidt H, Jauch A, Schonland SO.

Blood. 2008 May 1;111(9):4700-5. doi: 10.1182/blood-2007-11-122101. Epub 2008 Feb 27.

14.

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, Ludwig J, Perz JB, Ho AD, Goldschmidt H, Schonland SO.

Haematologica. 2008 Mar;93(3):459-62. doi: 10.3324/haematol.11687. Epub 2008 Feb 20.

15.

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).

Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD, Goldschmidt H.

Bone Marrow Transplant. 2007 Dec;40(11):1033-7. Epub 2007 Sep 24.

PMID:
17891186
16.

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.

Breitkreutz I, Lokhorst HM, Raab MS, Holt Bv, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IG, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H.

Leukemia. 2007 Jun;21(6):1294-9. Epub 2007 Mar 22.

PMID:
17377586
17.

Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, Cremer FW, Lowenthal RM, Huesing J, Fruehauf S, Moehler T, Ho AD, Goldschmidt H.

Eur J Haematol. 2007 Jan;78(1):21-8. Epub 2006 Sep 28.

PMID:
17042762
18.

Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery.

Zahlten-Hinguranage A, Goldschmidt H, Cremer FW, Egerer G, Moehler T, Witte D, Bernd L, Sabo D, Zeifang F.

Br J Cancer. 2006 Oct 9;95(7):782-7. Epub 2006 Sep 12.

19.

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De Vos J, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B.

Oncogene. 2006 Nov 16;25(54):7180-91. Epub 2006 May 29.

20.

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.

Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, Jüttner A, Schnurr T, Cremer F, Moehler T, Goldschmidt H, Busert B, Schubert R, Schwanitz G.

Cancer Genet Cytogenet. 2006 May;167(1):20-5.

PMID:
16682281
21.

Microarray-based understanding of normal and malignant plasma cells.

De Vos J, Hose D, Rème T, Tarte K, Moreaux J, Mahtouk K, Jourdan M, Goldschmidt H, Rossi JF, Cremer FW, Klein B.

Immunol Rev. 2006 Apr;210:86-104. Review.

22.

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O.

Exp Hematol. 2006 Apr;34(4):486-96.

23.

Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor.

Plaschke J, Linnebacher M, Kloor M, Gebert J, Cremer FW, Tinschert S, Aust DE, von Knebel Doeberitz M, Schackert HK.

Eur J Hum Genet. 2006 May;14(5):561-6.

24.

Chromosomal aberrations in follicular non-Hodgkin lymphomas of Japanese patients, detected with comparative genomic hybridization and polymerase chain reaction analysis.

D'Haese JG, Tsukasaki K, Cremer FW, Fischer C, Bartram CR, Jauch A.

Cancer Genet Cytogenet. 2005 Oct 15;162(2):107-14.

PMID:
16213357
25.

High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.

Cremer FW, Kartal M, Hose D, Bila J, Buck I, Bellos F, Raab MS, Brough M, Moebus A, Hager HD, Goldschmidt H, Moos M, Bartram CR, Jauch A.

Cancer Genet Cytogenet. 2005 Sep;161(2):116-24.

PMID:
16102581
26.

Distinct roles of GIGANTEA in promoting flowering and regulating circadian rhythms in Arabidopsis.

Mizoguchi T, Wright L, Fujiwara S, Cremer F, Lee K, Onouchi H, Mouradov A, Fowler S, Kamada H, Putterill J, Coupland G.

Plant Cell. 2005 Aug;17(8):2255-70. Epub 2005 Jul 8.

27.

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.

Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, Benner A, Raab MS, Theil AC, Moos M, Goldschmidt H, Bartram CR, Jauch A.

Genes Chromosomes Cancer. 2005 Oct;44(2):194-203.

PMID:
16001433
28.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B.

Blood. 2005 Aug 1;106(3):1021-30. Epub 2005 Apr 12.

29.

Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

Raab MS, Cremer FW, Breitkreutz IN, Gerull S, Luft T, Benner A, Goerner M, Ho AD, Goldschmidt H, Moos M.

Ann Oncol. 2005 Apr;16(4):611-7. Epub 2005 Feb 28.

PMID:
15737985
30.

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Mahtouk K, Hose D, Rème T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi JF, Cremer FW, Klein B.

Oncogene. 2005 May 12;24(21):3512-24.

31.

Long-term survival after surgical intervention for bone disease in multiple myeloma.

Zeifang F, Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Bernd L, Sabo D.

Ann Oncol. 2005 Feb;16(2):222-7.

PMID:
15668274
32.

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.

Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, Westveer PH, Sonneveld P, Goldschmidt H, Lokhorst HM.

Leukemia. 2004 Dec;18(12):2044-6. No abstract available.

PMID:
15470485
33.

A large MSH2 Alu insertion mutation causes HNPCC in a German kindred.

Kloor M, Sutter C, Wentzensen N, Cremer FW, Buckowitz A, Keller M, von Knebel Doeberitz M, Gebert J.

Hum Genet. 2004 Oct;115(5):432-8. Epub 2004 Aug 31.

PMID:
15340835
34.

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.

Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B, Benner A, Goldschmidt H, Moos M, Cremer FW.

Br J Haematol. 2004 Sep;126(5):665-74.

PMID:
15327517
35.

Distinct photoperiodic responses are conferred by the same genetic pathway in Arabidopsis and in rice.

Cremer F, Coupland G.

Trends Plant Sci. 2003 Sep;8(9):405-7. No abstract available.

PMID:
13678904
36.

[Multiple myeloma. Diagnosis and therapy].

Goldschmidt H, Cremer FW, Möhler TM, Ho AD.

Internist (Berl). 2003 May;44(5):599-600, 603-16; quiz 617-8. German.

PMID:
12966788
37.

Ultrasensitive PCR detection of tumor cells in myeloma.

Cremer FW, Moos M.

Methods Mol Biol. 2003;226:185-96. No abstract available.

PMID:
12958500
38.

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.

Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM; HOVON; GMMG.

Ann Hematol. 2003 Oct;82(10):654-9. Epub 2003 Jul 4. No abstract available.

PMID:
12845480
39.

Comprehensive genetic counseling for families at risk for HNPCC: impact on distress and perceptions.

Keller M, Jost R, Haunstetter CM, Kienle P, Knaebel HP, Gebert J, Sutter C, Knebel-Doeberitz Mv, Cremer F, Mazitschek U.

Genet Test. 2002 Winter;6(4):291-302.

PMID:
12537653
40.

Bisphosphonates in multiple myeloma.

Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.

Cochrane Database Syst Rev. 2002;(3):CD003188. Review. Update in: Cochrane Database Syst Rev. 2010;(3):CD003188.

PMID:
12137679
41.

Control of flowering time: interacting pathways as a basis for diversity.

Mouradov A, Cremer F, Coupland G.

Plant Cell. 2002;14 Suppl:S111-30. Review. No abstract available.

42.

Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation.

Gemmel C, Cremer FW, Weis M, Witzens M, Moldenhauer G, Koniczek KH, Imbach U, Ho AD, Moos M, Goldschmidt H.

Ann Hematol. 2002 Feb;81(2):119-23. Epub 2001 Dec 22.

PMID:
11907796
44.

Bisphosphonates in multiple myeloma.

Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.

Cochrane Database Syst Rev. 2001;(4):CD003188. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD003188.

PMID:
11687178
45.

The delayed terminal flower phenotype is caused by a conditional mutation in the CENTRORADIALIS gene of snapdragon.

Cremer F, Lönnig WE, Saedler H, Huijser P.

Plant Physiol. 2001 Jul;126(3):1031-41.

46.

Clonotypic B cells in the peripheral blood of patients with multiple myeloma.

Cremer FW, Goldschmidt H, Moos M.

Blood. 2001 May 1;97(9):2913-4. No abstract available.

47.
48.

CD19+ and CD20+ B cells from the peripheral blood of patients with multiple myeloma are not infected with human herpesvirus 8.

Bösing T, Bellos F, Cremer FW, Gemmel C, Moldenhauer G, Ho AD, Goldschmidt H, Moos M.

Leukemia. 2000 Jul;14(7):1330-1. No abstract available.

PMID:
10914566
50.

Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation.

Rottenburger C, Kiel K, Bösing T, Cremer FW, Moldenhauer G, Ho AD, Goldschmidt H, Moos M.

Br J Haematol. 1999 Aug;106(2):545-52.

PMID:
10460621

Supplemental Content

Loading ...
Support Center